Sugi Predict

Sugi Predict / Compounds / SCHEMBL805262

SCHEMBL805262

SCHEMBL805262

NC(=O)c1cnc(Cl)c([N+](=O)[O-])c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 1/20 0.49
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ VCAM1 P19320 2/20 0.44
▸ LMNA P02545 5/20 0.43
▸ POLB P06746 2/20 0.43
▸ MET P08581 1/20 0.43
▸ MAPT P10636 3/20 0.42
▸ ALDH1A1 P00352 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ PKM P14618 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ TSHR P16473 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ GPR35 Q9HC97 1/20 0.40
▸ HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL487379 0.85 CASP6 (0.51) VCAM1LMNAPOLBMETMAPT
SCHEMBL31090135 0.85 CASP6 (0.51) VCAM1LMNAPOLBMETMAPT
SCHEMBL2368685 0.85 VCAM1 (0.45) SMN1; SMN2VCAM1LMNAPOLBMAPT
SCHEMBL30305536 0.85 VCAM1 (0.45) SMN1; SMN2VCAM1LMNAPOLBMAPT
SCHEMBL1625709 0.83 MAPT (0.44) VCAM1LMNAPOLBMAPTALDH1A1
SCHEMBL4170811 0.81 PARP1 (0.50) PARP1SMN1; SMN2CYP3A4LMNAPOLB
SCHEMBL7180111 0.81 PARP1 (0.50) PARP1SMN1; SMN2CYP3A4LMNAMET
SCHEMBL31423765 0.81 PARP1 (0.50) PARP1SMN1; SMN2CYP3A4LMNAPOLB
SCHEMBL13670358 0.81 VCAM1 (0.41) SMN1; SMN2VCAM1LMNAPOLBMAPT
SCHEMBL16095613 0.80 PARP1 (0.49) PARP1SMN1; SMN2CYP3A4LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4007758-B1 BIS-[N-((5-CARBAMOYL)-1H-BENZO[D]IMIDAZOL-2-YL)-PYRAZOL-5-CARBOXAMIDE] DERIVATIVES AND RELATED COMPOUNDS AS STING (STIMULATOR OF INTERFERON GENES) AGONISTS FOR THE TREATMENT OF CANCER MERSANA THERAPEUTICS INC (US) 2026-05-13 — — EP disclosed
EP-4594318-A1 AKT1 MODULATORS Alterome Therapeutics, Inc. (US) 2025-08-06 — — EP disclosed
US-20250092040-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. 2025-03-20 — — US disclosed
US-20250011339-A1 STING AGONIST COMPOUNDS AND METHODS OF USE MERSANA THERAPEUTICS, INC. 2025-01-09 — — US disclosed
EP-4463450-A1 FUSED HETEROARYL HYDROXAMATES AS STING AGONISTS Bisichem Co., Ltd. (KR) 2024-11-20 — — EP disclosed
WO-2024186626-A1 AZA-BICYCLIC STING AGONIST IMMUNOCONJUGATES, AND USES THEREOF BOLT BIOTHERAPEUTICS, INC. (US) 2024-09-12 — — WO disclosed
CN-118510770-A Fused heteroaryl hydroxamic acids as STING agonists 比西切姆有限公司 2024-08-16 — — CN disclosed
US-20240239797-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. 2024-07-18 — — US disclosed
US-20240239797-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. 2024-07-18 — — US disclosed
US-11999730-B1 AKT1 modulators ALTEROME THERAPEUTICS, INC. (US) 2024-06-04 — — US disclosed
US-20140073796-A1 NITROPYRIDINYL ETHYLENEIMINE COMPOUND, THE PHARMACEUTICAL COMPOSITION CONTAINING IT, THE PREPARATION METHOD AND USE THEREOF BEIJING YILING BIOENGINEERING CO., LTD (CN) 2014-03-13 — — US disclosed
US-20120071515-A1 NITROPYRIDINYL ETHYLENEIMINE COMPOUND, THE PHARMACEUTICAL COMPOSITION CONTAINING IT, THE PREPARATION METHOD AND USE THEREOF BEIJING YILING BIOENGINEERING CO., LTD (CN) 2012-03-22 — — US disclosed
EP-2366691-A1 THE NITROPYRIDINYL ETHYLENEIMINE COMPOUND, THE PHARMACEUTICAL COMPOSITION CONTAINING IT, THE PREPARATION METHOD AND USE THEREOF Beijing Yiling Bioengineering Co., Ltd. (CN) 2011-09-21 — — EP disclosed
EP-0666858-B1 5-ARYLINDOLE DERIVATIVES AND THEIR USE AS SEROTONIN (5-HT 1) AGONISTS PFIZER (US) 2001-06-13 — — EP disclosed
EP-1094064-A1 5-arylindolederivatives and their use as serotonin(5-ht1)agonists PFIZER INC. (US) 2001-04-25 — — EP disclosed
CN-1051313-C 5-arylindole derivatives PFIZER (US) 2000-04-12 — — CN disclosed
US-5886008-A 5-arylindole derivatives PFIZER INC. (US) 1999-03-23 — — US disclosed
EP-0666858-A1 5-ARYLINDOLE DERIVATIVES AND THEIR USE AS SEROTONIN (5-HT 1?) AGONISTS PFIZER INC. (US) 1995-08-16 — — EP disclosed
CN-1094727-A The 5-(hetero) aryl indole derivatives PFIZER (US) 1994-11-09 — — CN disclosed
WO-1994010171-A1 5-ARYLINDOLE DERIVATIVES AND THEIR USE AS SEROTONIN (5-HT1) AGONISTS PFIZER INC. (US) 1994-05-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239797-A1 AKT1 MODULATORS AKT1S1, AKT1, AKT2 PARP1 1060/4885SMN1; SMN2 2237/4885CYP3A4 4570/4885
US-20120071515-A1 NITROPYRIDINYL ETHYLENEIMINE COMPOUND, THE PHARMACEUTICAL COMPOSITION CONTAINING IT, THE PREPARATION METHOD AND USE THEREOF ENPP1, DPYD, NME2 PARP1 311/4885SMN1; SMN2 3153/4885CYP3A4 90/4885
US-20140073796-A1 NITROPYRIDINYL ETHYLENEIMINE COMPOUND, THE PHARMACEUTICAL COMPOSITION CONTAINING IT, THE PREPARATION METHOD AND USE THEREOF ENPP1, DPYD, NME2 PARP1 311/4885SMN1; SMN2 3153/4885CYP3A4 90/4885
US-20250011339-A1 STING AGONIST COMPOUNDS AND METHODS OF USE STING1, IRF3, MAVS PARP1 536/4885SMN1; SMN2 2815/4885CYP3A4 4415/4885
US-20250092040-A1 AKT1 MODULATORS AKT1S1, AKT1, AKT2 PARP1 1060/4885SMN1; SMN2 2237/4885CYP3A4 4570/4885
US-11999730-B1 AKT1 modulators AKT1S1, AKT1, AKT2 PARP1 1060/4885SMN1; SMN2 2237/4885CYP3A4 4570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.